Home › NCT04946721

2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD

2177GCCC: Identifying Novel Treatment Targets and Biomarkers for Ocular Surface Disease in Patients With Ocular Graft vs Host Disease (oGVHD) a Biobank Study

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Adult patients (≥ 18 years of age) who visit the Eye clinic either in the UMGCCC within the UMD Hospital or the UMD Faculty Physicians Ophthalmology Practice at the UMD Professional Building or satellite locations for initial visits or established visits.
* The patient must be able to understand and sign and date the informed consent form approved by the IRB.

Exclusion Criteria:

* Vulnerable populations: neonates, children, prisoners, institutionalized individuals.
* Inability or refusal to provide informed consent.
* History of ocular surgery (except refractive surgery or cataract surgery)

About the study

Evaluate and study the immunologic changes to the ocular surface in cancer patients.

What is being tested

• The standard care exam and biological specimens' collection (diagnostic test)

Sponsor: University of Maryland, Baltimore · Participants: 150 · Started: Apr 27, 2022

Contact the study team

• Sarah B Sunshine, MD · Phone: 667-214-1292
• Patricia Lesho · Phone: 410-328-2577

Official record on ClinicalTrials.gov — NCT04946721

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.